PharmaJet, a commercial-stage leader in needle-free injection systems, announced the expansion of its technology portfolio with the development of proprietary needle-free self-injection pens designed for home use. The company is developing both single-use and reusable subcutaneous injection devices aimed at the chronic disease and metabolic peptide self-injection markets, with prototypes currently undergoing early testing.
Addressing Critical Market Barriers
The new injection pens are designed to overcome significant barriers in self-injectable drug delivery, particularly needle aversion and injection site pain that impact patient compliance. According to CEO Wouter Latour, "PharmaJet's needle-free injector pens aim to improve the user experience, reduce administration anxiety and discomfort, and simplify the injection procedure, especially for patients with mobility challenges."
The reusable PharmaJet injector pens may offer substantial advantages over current disposable technologies by reducing waste generation, addressing environmental concerns associated with traditional injection systems.
Proven Clinical Performance
PharmaJet's expansion builds on extensive clinical evidence from its existing Tropis intradermal needle-free injection system. More than 12 million vaccine injections have been administered worldwide using the Tropis system, with published research demonstrating significant clinical advantages over traditional needle and syringe methods.
Clinical data shows the Tropis system is preferred by over 95% of caregivers, while recipients reported substantial improvements in comfort, including 68% reduction in pain and 69% reduction in soreness compared to conventional injections. Recent research published in Vaccines demonstrated that Tropis use increased coverage rates in routine immunization compared to standard needle and syringe delivery, suggesting needle-free technology's potential to improve treatment compliance.
Technology Integration and Market Focus
The new subcutaneous injector pens will leverage PharmaJet's expertise in reusable needle-free delivery systems, incorporating smart e-technology for dose tracking and patient compliance support. The devices are intended for needle-free subcutaneous delivery of a wide range of pharmaceuticals, including metabolic peptides, hormones, small molecules, and antibodies.
"We are excited about the prospect of entering the pen injector market with the PharmaJet needle-free self-injector pens," said Latour. "The PharmaJet devices are being designed to provide a superior, user-experience to a wide group of patients, while offering smart e-technology to track dosing and support patient compliance."
Regulatory Foundation and Commercial Strategy
PharmaJet's existing systems have established regulatory pathways, with the Stratis System holding U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification for intramuscular or subcutaneous delivery. The Tropis System has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs.
The company plans to actively pursue industry partnerships in the coming months, particularly targeting the exponentially growing metabolic peptide segment and other markets requiring frequent injections. Dan Mallon, Senior Vice President of Corporate Development, noted that "recent evidence has attracted stakeholders across all stages of pharmaceutical development to exploring how alternative administration methods can add value to their injectables."
Clinical Development Applications
PharmaJet continues to demonstrate the clinical utility of its needle-free technology across various therapeutic areas. The company recently collaborated on a Phase 2 oncology trial for patients with advanced melanoma, highlighting the versatility of needle-free delivery systems in diverse clinical applications.
The Tropis intradermal delivery system, developed with support from the WHO, PATH, CDC, and Bill & Melinda Gates Foundation, was specifically designed to overcome obstacles associated with traditional Mantoux injection techniques, enabling precise, safe, scalable, and effective intradermal delivery that can be easily integrated into commercial products and development projects.
